RECOMBINANT HUMAN TNF ALPHA PHP051 from Bio-Rad (Formerly AbD Serotec)

Supplier Images
Published Figures

RECOMBINANT HUMAN TNF ALPHA

Published customer image:
Recombinant human TNF-α (PHP051) used to treat RSFLs prior to evaluation of VE-CDH by western blotting.
Image caption:
Protein expression of VE-cadherin species in RSFLs under the simulation.
(c) Immunoblot of intact and cytoplasmic fragment of VE-CDH in RSFL4 after treatment with cytokines or under hypoxia. The cells were treated with TNF-a in the absence or presence of VEGF₁₆₅ and under hypoxic conditions of 1% O₂ or deferoxamine treatment (DFX). Ctrl, control without treatment. (d) Protein band densities of VE-CDH (125 kDa and 35 kDa) in RSFL4 compared with Ctrl RSFL4.
From: Yamazaki N, et al.
VE-cadherin-dependent vasculogenic mimicry-like tube formation in rheumatoid arthritic synovium.
Research Square 10 October 2022.
doi: 10.21203/rs.3.rs-2127147/v1
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
RECOMBINANT HUMAN TNF ALPHA

Published customer image:
Recombinant human TNF-α (PHP051) used to treat RSFLs prior to evaluation of VE-CDH by western blotting.
Image caption:
Protein expression of VE-cadherin species in RSFLs under the simulation.
(c) Immunoblot of intact and cytoplasmic fragment of VE-CDH in RSFL4 after treatment with cytokines or under hypoxia. The cells were treated with TNF-a in the absence or presence of VEGF₁₆₅ and under hypoxic conditions of 1% O₂ or deferoxamine treatment (DFX). Ctrl, control without treatment. (d) Protein band densities of VE-CDH (125 kDa and 35 kDa) in RSFL4 compared with Ctrl RSFL4.
From: Yamazaki N, et al.
VE-cadherin-dependent vasculogenic mimicry-like tube formation in rheumatoid arthritic synovium.
.
doi: 10.21203/rs.3.rs-2127147/v1
This image is from an open access article distributed under terms of a.
RECOMBINANT HUMAN TNF ALPHA

Published customer image:
Recombinant human TNF-α (PHP051) used to treat RSFLs prior to evaluation of VE-CDH by western blotting.
Image caption:
Protein expression of VE-cadherin species in RSFLs under the simulation.
(c) Immunoblot of intact and cytoplasmic fragment of VE-CDH in RSFL4 after treatment with cytokines or under hypoxia. The cells were treated with TNF-a in the absence or presence of VEGF₁₆₅ and under hypoxic conditions of 1% O₂ or deferoxamine treatment (DFX). Ctrl, control without treatment. (d) Protein band densities of VE-CDH (125 kDa and 35 kDa) in RSFL4 compared with Ctrl RSFL4.
From: Yamazaki N, et al.
VE-cadherin-dependent vasculogenic mimicry-like tube formation in rheumatoid arthritic synovium.
Research Square 10 October 2022.
doi: 10.21203/rs.3.rs-2127147/v1
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
RECOMBINANT HUMAN TNF ALPHA

Published customer image:
Recombinant human TNF-α (PHP051) used to treat RSFLs prior to evaluation of VE-CDH by western blotting.
Image caption:
Protein expression of VE-cadherin species in RSFLs under the simulation.
(c) Immunoblot of intact and cytoplasmic fragment of VE-CDH in RSFL4 after treatment with cytokines or under hypoxia. The cells were treated with TNF-a in the absence or presence of VEGF₁₆₅ and under hypoxic conditions of 1% O₂ or deferoxamine treatment (DFX). Ctrl, control without treatment. (d) Protein band densities of VE-CDH (125 kDa and 35 kDa) in RSFL4 compared with Ctrl RSFL4.
From: Yamazaki N, et al.
VE-cadherin-dependent vasculogenic mimicry-like tube formation in rheumatoid arthritic synovium.
Research Square 10 October 2022.
doi: 10.21203/rs.3.rs-2127147/v1
This image is from an open access article distributed under terms of a Creative Commons Attribution License.